Thursday, May 19, 2016
Ochsner Health System announces its partnership with TriNetX, a leader in international clinical research data networks and a breakthrough disruptor of clinical trial design. Through this agreement, Ochsner clinicians will have improved ability to participate in clinical trials, making new therapies available to Ochsner patients sooner. The TriNetX global network represents 27 healthcare institutions with over 37 million patient lives and is expanding monthly. Industry sponsors are currently leveraging the network to design protocols with real world data and to more accurately match industry-sponsored clinical trials with the right sites and the right patient populations. Ochsner is the first healthcare institution in Louisiana to join the TriNetX network.
“We expect the TriNetX partnership to help accelerate our physicians’ access to clinical trials, and thereby our patients’ access to leading edge care,” said Sohail Rao, MD, MA, DPhil, System Vice President for Research at Ochsner. “It also means that Ochsner researchers have access to new tools with which to analyze data on our own patients and refine treatments. It can also help connect them with other institutions to enhance our research potential.”
Traditionally, pharmaceutical companies design clinical trials and protocols without knowing exactly where the required numbers of patients meeting their criteria can be found. Now, anonymous Ochsner patient data will be more readily available via REACHnet (a local clinical research network funded by the Patient-Centered Outcomes Research Institute) and TriNetX to assist this process.
“Our mission is to disrupt the clinical trial design space by unleashing the power of data that is currently locked away,” said Gadi Lachman, CEO, TriNetX. “Through our network, healthcare providers, pharmaceutical companies and contract research organizations can create strategic partnerships to improve clinical research and patient care, and we are honored to have Ochsner as part of our network. We see this collaboration agreement as a win-win for Ochsner, TriNetX, our member institutions, and ultimately patients.”
Ochsner physician scientists, pharmaceutical company researchers and Ochsner clinicians can now analyze patient populations with search criteria across multiple longitudinal data points. Each data point can ultimately be traced to healthcare providers who can, while maintaining patient privacy, identify individual patients for recruitment into clinical trials, confirm results and/or offer new treatment options.
Source : news.ochsner.org
